Alkermes plc (NASDAQ:ALKS) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP reduced its position in shares of Alkermes plc (NASDAQ:ALKS) by 40.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,947 shares of the company’s stock after selling 9,371 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Alkermes were worth $401,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Venturi Wealth Management LLC bought a new stake in shares of Alkermes in the 4th quarter worth approximately $25,000. EverSource Wealth Advisors LLC increased its holdings in shares of Alkermes by 106.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company’s stock valued at $47,000 after buying an additional 842 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Alkermes by 2,231.5% during the 4th quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock valued at $49,000 after acquiring an additional 1,629 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Alkermes by 558.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock worth $85,000 after acquiring an additional 2,502 shares in the last quarter. Finally, Cornerstone Investment Partners LLC acquired a new position in shares of Alkermes in the 4th quarter worth $203,000. 95.21% of the stock is currently owned by institutional investors.

Insider Transactions at Alkermes

In related news, EVP Craig C. Hopkinson sold 144,419 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the sale, the executive vice president now directly owns 57,875 shares in the company, valued at approximately $2,056,298.75. The trade was a 71.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.89% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Royal Bank of Canada assumed coverage on Alkermes in a research report on Thursday, March 13th. They issued a “sector perform” rating and a $40.00 price target for the company. StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Alkermes in a report on Tuesday, February 11th. They set a “buy” rating and a $40.00 price target on the stock. The Goldman Sachs Group raised their price objective on shares of Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, HC Wainwright reissued a “neutral” rating and set a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.46.

Alkermes Stock Performance

Shares of ALKS opened at $34.79 on Tuesday. The firm has a market cap of $5.66 billion, a PE ratio of 16.03, a PEG ratio of 2.20 and a beta of 0.62. The firm’s 50 day moving average price is $33.10 and its 200 day moving average price is $30.12. Alkermes plc has a twelve month low of $22.90 and a twelve month high of $36.45.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. On average, sell-side analysts anticipate that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.